Association between proton pump inhibitor use and anemia: A retrospective cohort study

Digestive Diseases and Sciences

Volumn 56, Issue 8, 2011, Pages 2349-2353

  Sarzynski, Erin ^a   Puttarajappa, Chethan ^b   Xie, Yan ^c   Grover, Madhusudan ^d   Laird Fick, Heather ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Anemia; Iron deficiency; Malabsorption; Proton pump inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ESOMEPRAZOLE; HEMOGLOBIN; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COLONOSCOPY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG USE; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; OUTPATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; ERYTHROCYTE INDICES; FEMALE; GASTRIC ACID; HEMATOCRIT; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79960963240     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1589-y     Document Type: Article

References (21)

1. IMS Health Report. 2009 top therapeutic classes by US dispensed prescriptions. Available at: http://www.imshealth.com/deployedfiles/imshealth/ Global/Content/StaticFile/Top-Line-Data/Top%20Therapy%20Classes%20by%20U.S.RXs. pdf. Accessed 9 June 2010.
2. IMS Health Report. 2009 top therapeutic classes by US sales. Available at: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/ Top-Line-Data/Top%20Therapy%20Classes%20by%20U.S.Sales.pdf. Accessed 9 June 2010.
3. Heidelbaugh J, Goldberg K, Inadomi J. Overutilization of proton pump inhibitors: A review of cost-effectiveness and risk in ppi. Am J Gastroenterol. 2009;104:S27-S32.
4. Pham C, Regal R, Bostwick T, Knauf K. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacotherapy. 2006;40:1261-1266.
5. Ho P,Maddox T,Wang L, et al.Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944.
6. Yang Y, Lewis J, Epstein S, Metz D. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947-2953. (Pubitemid 46021498)
7. Gulmez S, Holm A, Frederiksen H, Jensen T, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: A population-based case-control study. Arch Intern Med. 2007;167:950-955. (Pubitemid 46762758)
8. FDA drug safety communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors, 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm. Accessed May 25, 2010.
9. Koop H. Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment Pharmacol Ther. 1992;6:399-406.
10. Marcuard S, Albernaz L, Khazanie P. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin b12). Ann Intern Med. 1994;120:211-215.
11. Bezwoda W, Charlton R, Bothwell T, et al. The importance of gastric hydrochloric acid in the absorption of nonheme food iron. J Clin Gastroenterol. 2000;30:29-33.
12. Cook J, Brown G, Valberg L. The effect of achylia gastric on iron absorption. J Clin Invest. 1964;43:1185-1191.
13. Hines J, Hoffbrand A, Mollin D. The hematologic complications following partial gastrectomy. Am J Med. 1967;43:555-569.
14. Wheldon E, Venables C, Johnston I. Late metabolic sequelae of vagotomy and gastroenterostomy. Lancet. 1970;i:437-440.
15. Koop H, Bachem M. Serum iron, ferritin, and vitamin b12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14:288-292.
16. Stewart C, Termanini B, Sutliff V, et al. Iron absorption in patient with zollinger-ellison syndrome treated with long-term gastric antisecretory therapy. Aliment Pharmacol Ther. 1998;12:83-98. (Pubitemid 28057410)
17. Hutchinson C, Geissler C, Powell J, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56:1291-1295. (Pubitemid 47300432)
18. Sharma V, Brannon M, Carloss E. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J. 2004;97:887-889. (Pubitemid 39249673)
19. Schade S, Cohen R, Conrad M. Effect of hydrochloric acid on iron absorption. N Eng J Med. 1968;279:672-674.
20. Ali T, Roberts D, Tierney W. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122:896-903.
21. Nealis T, Howden C. Is there a dark side to long-term proton pump inhibitor therapy? Am J Therapeutics. 2008;15:536-542.